{'fraction_non_alphanumeric': 0.03042198233562316, 'fraction_numerical': 0.02747791952894995, 'mean_word_length': 5.181818181818182, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A population-based case-control teratologic study of furazidine, a nitrofuran-derivative treatment during pregnancy.

OBJECTIVE
To study human teratogenic potential of furazidine treatment during pregnancy.


DESIGN
Pair analysis of cases with congenital abnormalities and matched population controls.


SETTING
The Hungarian Case-Control Surveillance of Congenital Abnormalities.


PARTICIPANTS
38,151 pregnant women who had newborn infants without any defects (population control group) and 22,865 pregnant women who had newborns or fetuses with congenital abnormalities between 1980 and 1996.


RESULTS
In the case group, 157 (0.7%) and in the control group, 254 (0.7%) pregnant women were treated with furazidine. The case-control pair analysis did not indicate a teratogenic potential of furazidine use during the second to third months of gestation, i.e. in the critical period for major congenital abnormalities.


CONCLUSION
Treatment with furazidine during pregnancy did not show teratogenic risk to the fetus.